TR199902980T2 - Use of leptin antagonists for the treatment of diabetes. - Google Patents

Use of leptin antagonists for the treatment of diabetes.

Info

Publication number
TR199902980T2
TR199902980T2 TR1999/02980T TR9902980T TR199902980T2 TR 199902980 T2 TR199902980 T2 TR 199902980T2 TR 1999/02980 T TR1999/02980 T TR 1999/02980T TR 9902980 T TR9902980 T TR 9902980T TR 199902980 T2 TR199902980 T2 TR 199902980T2
Authority
TR
Turkey
Prior art keywords
treatment
diabetes
leptin antagonists
leptin
antagonists
Prior art date
Application number
TR1999/02980T
Other languages
Turkish (tr)
Inventor
Cawthorne Michael
Emilsson Valur
Liu Yong-Ling
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of TR199902980T2 publication Critical patent/TR199902980T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Insülin salgilanmasi, hiperglisemi ve insülin direncindeki aksamalardan kaynaklanan bozukluklarin tedavisi için bir ilacin yapiminda bir leptin antagonistinin kullanilmasi.The use of a leptin antagonist in the manufacture of a drug for the treatment of insulin secretion, hyperglycemia, and disorders caused by insulin resistance disruptions.

TR1999/02980T 1997-06-06 1997-06-06 Use of leptin antagonists for the treatment of diabetes. TR199902980T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1997/002240 WO1998055139A1 (en) 1997-06-06 1997-06-06 Use of leptin antagonists for the treatment of diabetes

Publications (1)

Publication Number Publication Date
TR199902980T2 true TR199902980T2 (en) 2000-05-22

Family

ID=8166613

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/02980T TR199902980T2 (en) 1997-06-06 1997-06-06 Use of leptin antagonists for the treatment of diabetes.

Country Status (9)

Country Link
EP (1) EP0986397A1 (en)
JP (1) JP2002504102A (en)
KR (1) KR20010013414A (en)
AU (1) AU2951797A (en)
CA (1) CA2293504A1 (en)
HU (1) HUP0003428A3 (en)
IL (1) IL133136A0 (en)
TR (1) TR199902980T2 (en)
WO (1) WO1998055139A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
WO2005077072A2 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
AU2006213607A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
BRPI0614649A2 (en) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc hybrid polypeptides with selectable properties
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
US20120071401A1 (en) 2009-04-10 2012-03-22 Amylin Pharamaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
EP2621519B1 (en) 2010-09-28 2017-06-28 Aegerion Pharmaceuticals, Inc. Leptin-abd fusion polypeptides with enhanced duration of action
JP6040464B2 (en) 2011-07-08 2016-12-07 アエゲリオン・ファーマシューティカルズ・インコーポレイテッドＡｅｇｅｒｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Engineered polypeptides with increased duration of action and reduced immunogenicity
DK2900230T3 (en) 2012-09-27 2018-11-12 Childrens Medical Ct Corp RELATIONSHIPS FOR TREATING ADIPOSITAS AND PROCEDURES FOR USING THEREOF
SI3074033T1 (en) 2013-11-26 2019-03-29 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
RS64850B1 (en) 2016-09-12 2023-12-29 Amryt Pharmaceuticals Inc Methods of detecting anti-leptin neutralizing antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
EP0836479A2 (en) * 1995-06-30 1998-04-22 Eli Lilly And Company Methods for treating diabetes

Also Published As

Publication number Publication date
CA2293504A1 (en) 1998-12-10
HUP0003428A3 (en) 2001-12-28
IL133136A0 (en) 2001-03-19
JP2002504102A (en) 2002-02-05
EP0986397A1 (en) 2000-03-22
WO1998055139A1 (en) 1998-12-10
KR20010013414A (en) 2001-02-26
AU2951797A (en) 1998-12-21
HUP0003428A2 (en) 2001-05-28

Similar Documents

Publication Publication Date Title
TR199902980T2 (en) Use of leptin antagonists for the treatment of diabetes.
EA200101156A1 (en) DRUG COMPOSITIONS OF A NEW TYPE ON THE BASIS OF POSSESSING HOLYNTHERGIC ACTION OF COMPOUNDS AND β-MIMETIC
DE60044041D1 (en) Exendine for glucagon suppression
ATE172971T1 (en) HETEROCYCLIC NEUROKININ ANTAGONISTS
IS2759B (en) CGRP receptor antagonists, drug preparations and use of the preparations for the manufacture of a drug
NO20053224D0 (en) Patient controlled drug administration device.
ZA200502247B (en) Selected CGRP antagonists, method for production and use thereof as medicament.
CO5011096A1 (en) MEDICINES CONTAINING ANTAGONISTS OF THE 5-HT3 RECEPTOR FOR THE TREATMENT OF IBS
ID21861A (en) USE OF LEPTIN ANTAGONISTS FOR TREATMENT OF RESISTANCE TOWARDS INSULIN IN TYPE II DIABETES
RS20060066A (en) Use of angiotensin ii receptor antagonists, especially telmisartan, in order to increase insulin sensitivity
DE60105922D1 (en) Portable, self-sufficient medication infusion device
DE60008374D1 (en) ANESTHETIC PREPARATION CONTAINING AN NMDA ANTAGONIST AND AN ALPHA-2 ADRENERGEN AGONIST
CY1105211T1 (en) DRUG COMBINATIONS INVOLVING A P2T RECEPTOR ANTAGONIST AND MELAGATRAN
ATE260650T1 (en) ORAL DOSAGE FORMS FOR ADMINISTRATION OF A FIXED COMBINATION OF TRAMADOL AND DICLOFENAC
PT1500654E (en) BENZOXAZINONE DERIVATIVES, ITS PREPARATION AND USE AS MEDICINES
DE69814394D1 (en) USE OF LEVOBUPIVACAIN
NZ337827A (en) Use of GluR5 receptor antagonists in the manufacture of medicaments for treating pain
ATE399010T1 (en) COMBINATION CONTAINING AN AT1 RECEPTOR ANTAGONIST AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITIZER
ID23799A (en) USING SPECIFICATION OF 5HT2 RECEPTOR ANTAGONISTS FOR THE MAKING OF MEDICINE USING USE IN TREATMENT OF APNEA SYNDROME IN SLEEP
DK0981347T3 (en) The use of levobupivacaine in facial surgery
IL184121A0 (en) Urotensin-ii agonists polypeptide and its use for manufacture of medicaments
BR0109342B1 (en) Medical needle used as a dental or insulin needle.
AR031122A1 (en) USE OF ENDOTHELINE ANTAGONISTS IN THE MANUFACTURE OF USEFUL MEDICINES FOR THE TREATMENT OF CANCER AND PAIN ASSOCIATED WITH THE SAME
NO995940L (en) Use of leptin antagonists for the treatment of diabetes
DK1244438T3 (en) Use of beta-adrenoceptor antagonists in the manufacture of a medicament for the treatment of diseases of the outer retina